Table 7.
Critical appraisal for included Cohorts via the NOS tool.
| Source | Aetiology | Selection 1-representativeness | Selection 2-non exposed | Selection 3- Ascertainment of exposure | Selection 4- outcome of interest | Comparability | Outcome 1- assessment | Outcome 2- length of follow up | Outcome 3- adequate length of following | Final quality |
|---|---|---|---|---|---|---|---|---|---|---|
| Zhou et al. (1) | SARS-CoV-2 | 1(b) | 1(a) | 1(a) | Yes(a) | 2(a-b) | 1(a) | 1(a) | 0(d) | Good quality |
| Qui et al. (2) | SARS-CoV-2 | 1(a) | 1(a) | 0(e) | 1(a) | 1(b) | 1(b) | 1(a) | 0(d) | Poor quality |
| Lo et al. (3) | SARS-CoV-2 | 1(b) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 0(d) | Poor quality |
| Wang et al. (4) | SARS-CoV-2 | 1(b) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 0(d) | Poor quality |
| Jin et al. (5) | SARS-CoV-2 | 1(a) | 1(a) | 1(a) | 0(b) | 0(c) | 1(b) | 1(a) | 1(b) | Good quality |
| Fan et al. (6) | SARS-CoV-2 | 1(a) | 1(a) | 1(a) | 0(b) | 0(c) | 1(a) | 1(a) | 1(a) | Fair quality |
| Sun et al. (7) | SARS-CoV-2 | 1(a) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 0(d) | Fair quality |
| To et al. (8) | SARS-CoV-2 | 1(a) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 0(d) | Poor quality |
| Yuan et al. (9) | SARS-CoV-2 | 1(a) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 0(d) | Poor quality |
| Cheng et al. (10) | SARS-CoV-2 | 1(a) | 1(a) | 1(a) | 1(a) | 2(a-b) | 1(a) | 1(a) | 1(a) | Good quality |
| Huang et al. (11) | SARS-CoV-2 | 0(c) | 0(c) | 1(a) | 1(a) | 0(c) | 1(a) | 1(a) | 0(d) | Poor quality |
| Habib et al. (12) | MERS-CoV | 0(c) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 1(a) | Poor quality |
| Arabi et al. (13) | MERS-CoV | 1(a) | 1(a) | 1(a) | 1(a) | 2(a-b) | 1(b) | 1(a) | 1(a) | Good quality |
| Alfaraj et al. (14) | MERS-CoV | 0(d) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 1(a) | Poor quality |
| Garout et al. (15) | MERS-CoV | 0(d) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 1(a) | Poor quality |
| Sherbini et al. (16) | MERS-CoV | 0(d) | 1(a) | 1(a) | 1(a) | 0(c) | 1(a) | 1(a) | 1(a) | Poor quality |
| Khalid et al. (17) | MERS-CoV | 0(d) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 1(a) | Poor quality |
| Choi et al. (18) | MERS-CoV | 0(d) | 1(a) | 1(a) | 1(a) | 0(c) | 1(a) | 1(a) | 1(a) | Poor quality |
| Al-Hameed et al.(19) | MERS-CoV | 1(b) | 0(c) | 1(a) | 1(a0 | 0(c) | 0(c) | 1(a) | 1(a) | Poor quality |
| Al-Ghamdi et al.(20) | MERS-CoV | 0(d) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 1(a) | Poor quality |
| Shalhoub (2015) et al. (21) | MERS-CoV | 1(a) | 1(a) | 1(a) | 1(a) | 2(a-b) | 1(b) | 1(a) | 1(a) | Good quality |
| Omrani et al. (22) | MERS-CoV | 1(a) | 1(a) | 1(a) | 1(a) | 0(c) | 1(b) | 1(a) | 1(a) | Poor quality |
| Loutfy et al. (23) | SARS-CoV-1 | 1(a) | 1(a) | 1(a) | 1(a) | 2(a-b) | 1(b) | 1(a) | 1(a) | Good quality |
Abbreviations: CD: Cannot be determined, MERS-CoV: Middle-Eastern respiratory syndrome coronavirus, NA: Not applicable, NR: Not Reported, SARS-CoV: severe acute respiratory syndrome coronavirus.
References.
1. Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, et al. Interferon-α2b Treatment for COVID-19. Frontiers in Immunology. 2020;11:1061.
2. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. The Lancet Infectious Diseases. 2020.
3. Lo IL, Lio CF, Cheong HH, Lei CI, Cheong TH, Zhong X, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. International journal of biological sciences. 2020;16(10):1698.
4. Wang X, Liu W, Zhao J, Lu Y, Wang X, Yu C, et al. Clinical characteristics of 80 hospitalized frontline medical workers infected with COVID-19 in Wuhan, China. Journal of Hospital Infection. 2020.
5. Jin X, Lian J-S, Hu J-H, Gao J, Zheng L, Zhang Y-M, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002-9.
6. Fan L, Liu C, Li N, Liu H, Gu Y, Liu Y, et al. Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study. medRxiv. 2020.
7. Sun D, Li H, Lu X-X, Xiao H, Ren J, Zhang F-R, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World Journal of Pediatrics. 2020:1-9.
8. To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases. 2020.
9. Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. Inflammation Research. 2020:1-8.
10. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney impairment is associated with in-hospital death of COVID-19 patients. medRxiv. 2020.
11. Huang Y, Zhou H, Yang R, Xu Y, Feng X, Gong P. Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China. medRxiv. 2020.
12. Habib AMG, Ali MAE, Zouaoui BR, Taha MAH, Mohammed BS, Saquib N. Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection. BMC infectious diseases. 2019;19(1):1–6.
13. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2019.
14. Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA. Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study. Travel Medicine and Infectious Disease. 2019;29:48-50.
15. Garout MA, Jokhdar HA, Aljahdali IA, Zein AR, Goweda RA, Hassan-Hussein A. Mortality rate of ICU patients with the Middle East Respiratory Syndrome-Coronavirus infection at King Fahad Hospital, Jeddah, Saudi Arabia. Central European journal of public health. 2018;26(2):87–91.
16. Sherbini N, Iskandrani A, Kharaba A, Khalid G, Abduljawad M, Al-Jahdali H. Middle East respiratory syndrome coronavirus in Al-Madinah City, Saudi Arabia: Demographic, clinical and survival data. Journal of Epidemiology and Global Health. 2017;7(1):29–36.
17. Khalid I, Alraddadi BM, Dairi Y, Khalid TJ, Kadri M, Alshukairi AN, et al. Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS. Respir Care. 2016;61(3):340-8.
18. Choi WS, Kang C-I, Kim Y, Choi J-P, Joh JS, Shin H-S, et al. Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea. Infection & chemotherapy. 2016;48(2):118-26.
19. Al-Hameed F, Wahla AS, Siddiqui S, Ghabashi A, Al-Shomrani M, Al-Thaqafi A, et al. Characteristics and outcomes of Middle East respiratory syndrome coronavirus patients admitted to an intensive care unit in Jeddah, Saudi Arabia. Journal of intensive care medicine. 2016;31(5):344-8.
20. Al Ghamdi M, Alghamdi KM, Ghandoora Y, Alzahrani A, Salah F, Alsulami A, et al. Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia. BMC infectious diseases. 2016;16(1):174.
21. Shalhoub S, Farahat F, Al-Jiffri A, Simhairi R, Shamma O, Siddiqi N, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother. 2015;70(7):2129-32.
22. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. The Lancet Infectious Diseases. 2014;14(11):1090-5.
23. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Jama. 2003;290(24):3222-8.